Skip to main content
. Author manuscript; available in PMC: 2014 Jan 14.
Published in final edited form as: Int J Cancer. 2012 Nov 26;132(10):2327–2338. doi: 10.1002/ijc.27918

Figure 3.

Figure 3

Human PBMC express JAM-1 and bind reovirus on their cell surface in the presence of neutralising human serum. (a) SW480 and SW620s were treated with 0 or 10 pfu per cell reovirus in the presence of 10% FCS, 1 or 2% HS. After 72 hr, cell viability was assessed by PI staining. Graph shows mean + SEM from three independent experiments. (b) PBMC were isolated from healthy donor blood, and cell-surface expression of JAM-1 within CD4+, CD8+, CD3-CD56+, CD14+ and CD19+ populations was determined by flow cytometry (black line: JAM-1; shaded grey: isotype-matched control). Plots are representative of three independent experiments. (c) PBMC were isolated from healthy donor blood and treated with 0, 1 or 10 pfu per cell reovirus for 4 hr in the presence of 7.5% HS. Cell-surface binding of reovirus σ3 antibody within CD4+, CD8+, CD3-CD56+, CD14+ and CD19+ populations was determined by flow cytometry. Plots are representative of three independent experiments. Statistical significance is denoted by *p < 0.05.